The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
22 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $18,204,658 in first-year total cost, median $767,002.
Most frequent study sections
- Drug Discovery for the Nervous System Study Section[DDNS]21
- Drug Discovery for the Nervous System Study Section[DDNS-R]1
Most frequent institutions
- JOHNS HOPKINS UNIVERSITY3
- EMORY UNIVERSITY2
- MASSACHUSETTS GENERAL HOSPITAL2
- SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE2
- CLEVELAND CLINIC LERNER COM-CWRU1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2022 | PET ligand discovery for arginine vasopressin1R01MH128705-01 | LIANG, STEVEN H | EMORY UNIVERSITY, GA | $1,043,141 | DDNS |
| 2022 | Preventing Tau uptake by novel inhibitors of tau binding to LRP11R01AG075084-01 | JACKSON, MICHAELKOSIK, KENNETH STEPHEN | UNIVERSITY OF CALIFORNIA SANTA BARBARA, CA | $885,722 | DDNS |
| 2022 | Subtype-selective NMDA ligands for Alzheimer's Disease1R01AG075444-01 | LIANG, STEVEN H | EMORY UNIVERSITY, GA | $782,248 | DDNS |
| 2022 | 5-HT2 Receptor Allosterism in Cocaine Use Disorder2R01DA038446-06A1 | CUNNINGHAM, KATHRYN A.ZHOU, JIA | UNIVERSITY OF TEXAS MED BR GALVESTON, TX | $537,543 | DDNS |
| 2022 | Macrophage-targeted dendrimer 2-PMPA for the treatment of age-related sarcopenia1R01AG078181-01 | HOKE, AHMETRANGARAMANUJAM, KANNANSLUSHER, BARBARA STAUCH | JOHNS HOPKINS UNIVERSITY, MD | $476,442 | DDNS |
| 2022 | Discovery of apoE4 modulators for Alzheimer’s disease therapy1R01AG078615-01 | CHUNG, THOMAS D YLI, YONGHE | MAYO CLINIC JACKSONVILLE, FL | $467,938 | DDNS |
| 2022 | Novel GLT-1 activators for the treatment of alcohol dependence: preclinical studies1R01AA029674-01A1 | ABOU-GHARBIA, MAGIDSARI, YOUSSEF | UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS, OH | $437,019 | DDNS |
| 2021 | Discovery of functionally selective dopamine ligands for age-related cognitive decline1RF1AG071675-01 | DOKHOLYAN, NIKOLAYMAILMAN, RICHARD BYANG, YANG | PENNSYLVANIA STATE UNIV HERSHEY MED CTR, PA | $1,464,036 | DDNS |
| 2021 | cGAS inhibitors for Alzheimer's disease treatment1R01AG074541-01 | GAN, LISINHA, SUBHASH C | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $847,498 | DDNS |
| 2021 | Ligand discovery for delineating cholesterol homeostasis in the brain1R01AG070060-01 | LIANG, STEVEN H | MASSACHUSETTS GENERAL HOSPITAL, MA | $808,990 | DDNS |
| 2021 | A Cytochrome P450 Therapeutic Space for Tauopathies1R56AG066712-01A1 | CAGAN, ROSS LEIGHDAR, ARVIN | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, NY | $801,925 | DDNS |
| 2021 | AMPAR ligand discovery for Alzheimer's disease1RF1AG073428-01 | LIANG, STEVEN H | MASSACHUSETTS GENERAL HOSPITAL, MA | $384,165 | DDNS |
| 2020 | Identification of small molecule inhibitors of tau pathology utilizing a novel primary neuronal assay.1RF1AG066569-01 | BRUNDEN, KURT R. | UNIVERSITY OF PENNSYLVANIA, PA | $2,245,547 | DDNS |
| 2020 | Novel Antagonists of the N-terminal Domain of the CRF Receptor Type 1 for Alzheimer's Disease1RF1AG065385-01 | RISSMAN, ROBERT | VETERANS MEDICAL RESEARCH FDN/SAN DIEGO, CA | $1,728,235 | DDNS |
| 2020 | Development of STEP Allosteric Inhibitors as Novel Therapeutics for Alzheimer's Disease1R01AG065387-01A1 | TAUTZ, LUTZ | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $958,279 | DDNS |
| 2020 | Pro-Electrophilic Drugs PEDs for Alzheimer's Disease1R56AG065372-01 | LIPTON, STUART A | SCRIPPS RESEARCH INSTITUTE, THE, CA | $885,611 | DDNS |
| 2020 | Discovery of Selective Inhibitors for the EphA4 Kinase1R01AG062617-01A1 | PASQUALE, ELENA BSERGIENKO, EDUARD A. | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $751,756 | DDNS |
| 2020 | Development of mGlu7 receptor allosteric modulators for neurological and psychiatric disorders1R01MH124671-01 | LINDSLEY, CRAIGNISWENDER, COLLEEN M | VANDERBILT UNIVERSITY, TN | $741,117 | DDNS |
| 2020 | Development of GCPII inhibitors for the treatment of age-related cognitive disorders1R01AG068130-01 | ARNSTEN, AMY F.T.SLUSHER, BARBARA STAUCHTSUKAMOTO, TAKASHI | JOHNS HOPKINS UNIVERSITY, MD | $720,931 | DDNS |
| 2020 | Non-beta-lactam GLT-1 activators: characterization in preclinical models of opioid and cocaine addiction1R01DA051205-01 | RAWLS, SCOTT M.REITZ, ALLEN B | TEMPLE UNIV OF THE COMMONWEALTH, PA | $455,516 | DDNS |
| 2020 | Early Stage Studies of a Novel Positive Allosteric Modulator of the Alpha1-Adrenergic Receptor to Treat Alzheimer's Disease1R01AG066627-01 | PEREZ, DIANNE M | CLEVELAND CLINIC LERNER COM-CWRU, OH | $402,083 | DDNS |
| 2020 | Dendrimer-conjugated nSMase2 inhibitor as a novel therapeutic approach for Alzheimer's Disease1R01AG063831-01A1 | RAIS, RANARANGARAMANUJAM, KANNANSLUSHER, BARBARA STAUCH | JOHNS HOPKINS UNIVERSITY, MD | $378,916 | DDNS |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.